Roivant Sciences licensed a drug from Pfizer for regulatory approval.
2 reports, 1 independent
Updated Sep 8
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Roivant Sciences licensed a drug from Pfizer for regulatory approval.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
-
Roivant Sciences (United States)
company in New York, United States
Related events
- FDA and Pfizer are seeking regulatory approval for their products.
- FDA granted approval for Pfizer's updated vaccine on September 2, 2025.
- Pfizer is jointly marketing the drug Eliquis.
- A drug developed by Roivant/Priovant Therapeutics received FDA approval for the treatment of dermatomyositis.
- Roivant Sciences identifies a potential market for its successful drug candidate in Europe.